Medicis Aesthetics Inc. is asking the FDA to expand the use of its flagship Restylane facial wrinkle filler for lip augmentation procedures.

The Scottsdale, Ariz.-based division of Medicis Pharmaceutical Corp. (NYSE:MRX) secured a panel date with the FDA’s General and Plastic Surgery Devices Panel April 27.

Restylane already has an indication from the Food & Drug Administration as a dermal injection used to fill moderate to severe facial wrinkles in the nasolabial folds, more commonly known as smile lines. The company wants to expand that indication to attack the popular lip augmentation market.

The FDA typically makes reviewer documents available for the public within two days of the meeting.